Detalhe da pesquisa
1.
Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial.
Oncologist
; 2024 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38815151
2.
Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G.
Oncologist
; 2024 Jun 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38873934
3.
Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort.
Invest New Drugs
; 42(1): 127-135, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38270822
4.
Azacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia: Children's Oncology Group trial AALL15P1.
Haematologica
; 2024 Jun 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38867582
5.
A phase 1 trial utilizing a pharmacokinetic endpoint to determine the optimal dose of ramucirumab in children and adolescents with relapsed or refractory solid tumors, including central nervous system tumors.
Pediatr Blood Cancer
; 71(3): e30817, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38189770
6.
A phase 1/2 study of pepinemab in children, adolescents, or young adults with recurrent or refractory solid tumors: A children's oncology group consortium report (ADVL1614).
Pediatr Blood Cancer
; 71(6): e30938, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38520670
7.
Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma.
Cancer
; 129(14): 2245-2255, 2023 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37081608
8.
Bioavailability and Pharmacokinetics of Endoxifen in Female Rats and Dogs: Evidence to Support the Use of Endoxifen to Overcome the Limitations of CYP2D6-Mediated Tamoxifen Metabolism.
Drug Metab Dispos
; 51(2): 183-192, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36351835
9.
Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712.
Pediatr Blood Cancer
; 70(12): e30672, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37710306
10.
Palbociclib in combination with chemotherapy in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia and lymphoma: A Children's Oncology Group study (AINV18P1).
Pediatr Blood Cancer
; 70(11): e30609, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37553297
11.
Sorbitol Is a Severity Biomarker for PMM2-CDG with Therapeutic Implications.
Ann Neurol
; 90(6): 887-900, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34652821
12.
Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies.
Invest New Drugs
; 40(1): 115-123, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34515877
13.
Nickel Isotope Fractionation As an Indicator of Ni Sulfide Precipitation Associated with Microbially Mediated Sulfate Reduction.
Environ Sci Technol
; 56(12): 7954-7962, 2022 06 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35648622
14.
The lower energy diffraction and scattering side-bounce beamline for materials science at the Canadian Light Source.
J Synchrotron Radiat
; 28(Pt 3): 961-969, 2021 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33950004
15.
Combined local delivery of tacrolimus and stem cells in hydrogel for enhancing peripheral nerve regeneration.
Biotechnol Bioeng
; 118(7): 2804-2814, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33913523
16.
A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515).
Pediatr Blood Cancer
; 68(9): e29065, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33881209
17.
A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phase-Clinical Trial Network (PEP-CTN).
Pediatr Blood Cancer
; 68(4): e28892, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33438318
18.
Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
Lancet Oncol
; 21(4): 541-550, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32192573
19.
Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer.
Breast Cancer Res
; 22(1): 51, 2020 05 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32430040
20.
ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study.
Cancer
; 126(24): 5303-5310, 2020 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32914879